Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

The unclear role of PET–CT in localized radiorecurrent prostate cancer

Prostate cancer recurrence is common after radical radiotherapy and the increasing use of novel, minimally invasive salvage treatments means that accurate detection and localization of radiorecurrent disease is vital in treatment planning and delivery. PET–CT is increasingly used to detect metastatic disease; however, data regarding its value for identifying and accurately characterizing intraprostatic recurrence need improvement.

This is a preview of subscription content, access via your institution

Access options

Buy article

Get time limited or full article access on ReadCube.

$32.00

All prices are NET prices.

References

  1. National Prostate Cancer Audit. NPCA Annual Report 2020 (National Prostate Cancer Audit, 2021).

  2. Zumsteg, Z. S. et al. The natural history and predictors of outcome following biochemical relapse in the dose escalation era for prostate cancer patients undergoing definitive external beam radiotherapy. Eur. Urol. 67, 1009–1016 (2015).

    Article  Google Scholar 

  3. Gaur, S. & Turkbey, B. Prostate MR imaging for posttreatment evaluation and recurrence. Radiol. Clin. North Am. 56, 263–275 (2018).

    Article  Google Scholar 

  4. Shah, T. T. et al. Magnetic resonance imaging and targeted biopsies compared to transperineal mapping biopsies before focal ablation in localised and metastatic recurrent prostate cancer after radiotherapy. Eur. Urol. 81, 598–605 (2022).

    Article  Google Scholar 

  5. Crocerossa, F. et al. Detection rate of prostate specific membrane antigen tracers for positron emission tomography/computerized tomography in prostate cancer biochemical recurrence: a systematic review and network meta-analysis. J. Urol. 205, 356–369 (2021).

    Article  Google Scholar 

  6. Valle, L. F. et al. A systematic review and meta-analysis of local salvage therapies after radiotherapy for prostate cancer (MASTER). Eur. Urol. 80, 280–292 (2021).

    Article  Google Scholar 

  7. Kanthabalan, A. et al. Intraprostatic cancer recurrence following radical radiotherapy on transperineal template mapping biopsy: implications for focal ablative salvage therapy. J. Urol. 204, 950–955 (2020).

    Article  CAS  Google Scholar 

  8. Golbari, N. M. & Katz, A. E. Salvage therapy options for local prostate cancer recurrence after primary radiotherapy: a literature review. Curr. Urol. Rep. 18, 63 (2017).

    Article  Google Scholar 

  9. Fendler, W. P. et al. False positive PSMA PET for tumor remnants in the irradiated prostate and other interpretation pitfalls in a prospective multi-center trial. Eur. J. Nucl. Med. Mol. Imaging 48, 501–508 (2021).

    Article  CAS  Google Scholar 

  10. Perera, M. et al. Gallium-68 prostate-specific membrane antigen positron emission tomography in advanced prostate cancer-updated diagnostic utility, sensitivity, specificity, and distribution of prostate-specific membrane antigen-avid lesions: a systematic review and meta-analysis. Eur. Urol. 77, 403–417 (2020).

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Taimur T. Shah.

Ethics declarations

Competing interests

H.U.A. receives core funding from the UK National Institute of Health Research (NIHR) Imperial Biomedical Research Centre, the Wellcome Trust, the UK NIHR, the UK Medical Research Council, Cancer Research UK, Prostate Cancer UK, The Urology Foundation, the BMA Foundation, Imperial Healthcare Charity, Sonacare, Trod Medical and Sophiris Biocorp; has received a travel allowance from Sonacare; was a paid consultant for Sophiris Biocorp and Sonacare; and is a proctor for Rezūm treatment and cryotherapy for Boston Scientific. The other authors declare no competing interests.

Supplementary information

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Light, A., Ahmed, H.U. & Shah, T.T. The unclear role of PET–CT in localized radiorecurrent prostate cancer. Nat Rev Urol 19, 573–574 (2022). https://doi.org/10.1038/s41585-022-00635-9

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s41585-022-00635-9

Search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing